SOHO 2018 | CAR T across hematological malignancies: trials to watch

John Rossi

Axicabtagene ciloleucel, an anti-CD19 CAR T-cell product, has shown impressive efficacy in diffuse large B-cell lymphoma already. In this video, recorded at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting held in Houston, TX, John Rossi, MS, from Kite Pharma Inc., Santa Monica, CA, highlights clinical trials in the ZUMA series which are targeting a variety of B-cell malignancies and leukemias with axicabtagene ciloleucel. He also discusses KITE 585, an anti-BCMA CAR T product which is being tested at Phase 1 (NCT03318861) in multiple myeloma.

Share this video